Ontology highlight
ABSTRACT:
SUBMITTER: Verstovsek S
PROVIDER: S-EPMC4380721 | biostudies-literature | 2015 Apr
REPOSITORIES: biostudies-literature
Verstovsek Srdan S Mesa Ruben A RA Gotlib Jason J Levy Richard S RS Gupta Vikas V DiPersio John F JF Catalano John V JV Deininger Michael W N MW Miller Carole B CB Silver Richard T RT Talpaz Moshe M Winton Elliott F EF Harvey Jimmie H JH Arcasoy Murat O MO Hexner Elizabeth O EO Lyons Roger M RM Raza Azra A Vaddi Kris K Sun William W Peng Wei W Sandor Victor V Kantarjian Hagop H
Haematologica 20150123 4
In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall survival benefit relative to placebo in patients with intermediate-2 or high-risk myelofibrosis. This planned analysis assessed the long-term efficacy and safety of ruxolitinib at a median follow-up of 149 weeks. At data cutoff, approximately 50% of patients originally randomized to ...[more]